Skip to main navigation Skip to search Skip to main content

Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification (Hypertension Research, (2023), 46, 1, (19-31), 10.1038/s41440-022-01036-6)

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The original version of this article incorrectly stated the dosage of 6-diazo-5-oxo-L-norleucine (DON) in animal studies. The unit of DON was incorrect; it should be 3 μg/g. There are three errors regarding units of DON in “DON administration study” in Methods, “DON administration reduces tissue O-GlcNAc levels and the MR protein levels in db/db mice” in Results and the caption of Fig. 5E. The original article has been corrected.

Original languageEnglish
Pages (from-to)814
Number of pages1
JournalHypertension Research
Volume46
Issue number3
DOIs
Publication statusPublished - 2023 Mar

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification (Hypertension Research, (2023), 46, 1, (19-31), 10.1038/s41440-022-01036-6)'. Together they form a unique fingerprint.

Cite this